Therefore, it is possible that TMEM106B might have more general effects on neurodegenerative diseases associated with defects of the endolysosomal pathway, such as Alzheimer’s disease and Parkinson’s disease, than previously believed. This evidence concerns the gene TMEM106B and early-onset autosomal dominant Alzheimer disease.